Published in Genetics and Environmental Business Week, June 29th, 2006
"Our DNAPrint Pharmaceuticals, Inc. subsidiary continued to move forward with the development of PT-401, a 'Super EPO' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients, the company's first drug, and we experienced a considerable revenue increase in our genotyping services and legacy ancestry business with our A NCESTRYbyDNA product," Gabriel stated.
Revenues in the first quarter of 2006...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week